PRECISION RESEARCH
AND DEVELOPMENT

ACCELERATES

ACCESS TO CARE

Bringing novel therapies to market is

costly and time consuming.

$1B
Average R&D costs
for novel therapeutics

52%
Respiratory drugs that fail
at phase III and beyond

Bringing novel therapies
to market is

costly and time consuming.

$1B
Average R&D costs for novel therapeutics

52%
Respiratory drugs that fail at phase III and beyond

AI-based solutions improve patient selection and help predict drug efficacy.

VIDA Discovery modernizes the clinical trial process

VIDA provides quality, quantitative CT imaging analysis for all major lung and respiratory diseases to streamline clinical trials with leading protocols.

  • 50+ Lung Imaging Biomarkers Dictionary
  • 500+ participating sites
  • Large Curated Data Repository
  • Patented Algorithms 
  • Phantom Access/Calibration Program
  • FDA, CE, TGA and CMDCAS certified
  • ISO-13485 compliant core lab process

ENHANCE PATIENT SELECTION

AI generated imaging biomarkers & advanced analytics ensure the strongest candidate selection criteria

BOOST
STUDY POWER

Advanced imaging endpoints often enables fewer clinical subjects for statistical significance while increasing sensitivity

IMPROVE CLINICAL EFFICACY

Lung imaging biomarkers can reveal a clear understanding of treatment effects and enable faster decisions

8

Languages
supported

30

Countries
engaged

13

Years of clinical trial
experience

20

Academic
partners

200

Peer-reviewed
publications

8

Languages supported

30

Countries engaged

13

Years of clinical trial experience

20

Academic partners

200

Peer-reviewed publications

60+ successful academic and industry clinical trials

60+ successful academic and industry clinical trials

What lung care professionals say about VIDA

“I’ve enjoyed working with VIDA for several years now and hope to do so also in future trials. They are, in my opinion, the provider with the best understanding (by far) of the challenges involved in using CT imaging in COPD/asthma clinical trials.”

Senior Scientist, Leading Pharma Company

“I’ve worked with VIDA for over 10 years. They are the scientific leader in the field. I’ve found their imaging analysis to be invaluable for evaluating lung phenotypes, including assessing response to biologic therapy in asthma patients.”

Mario Castro, MD, Professor of Pulmonary and Critical Care Medicine

PORTAL SUPPORT